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Although adriamycin (Doxorubicin) is one of the most
effective and useful antineoplastic agents for the treatment of
a variety of malignancies, its repeated administration can
induce irreversible myocardial damage and resultant heart
failure. Currently, no marker to detect early cardiac damage
is available. The purpose of this study was to investigate
whether an assessment of the acoustic properties of the myo-
cardium could enable the earlier detection of myocardial
damage after adriamycin chemotherapy. Forty Wistar rats were
treated with adriamycin (2 mg/kg, i.v.) once a week for 2, 4,
6 or 8 weeks consecutively. Left ventricular ejection fraction
(LVEF) was calculated using M-mode echocardiography data.
The magnitude of cardiac cycle dependent variation of inte-
grated backscatter (CVIB) of the myocardium was measured
in the mid segment of the septum and in the posterior wall
of the left ventricle, using a real time two dimensional inte-
grated backscatter imaging system. LVEF was significantly
lower in the adriamycin-treated 8-week group than in the
controls (75 ± 9 vs 57 ± 8%, p < 0.05). Myocyte damage was
only seen in the 8-week adriamycin-treated group. However,
no significant changes of CVIB were observed between base-
line or during follow-up in the ADR or control group. In con-
clusion, serial assessment of the acoustic properties of the
myocardium may not be an optimal tool for the early detection
of myocardial damage after doxorubicin chemotherapy in a rat
model.
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INTRODUCTION
Adriamycin, ADR (Doxorubicin HCl) is one of
the most effective and useful antineoplastic agents
for the treatment of a variety of malignancies.
However, cardiotoxicity, which may ultimately
lead to congestive heart failure, is a well known
problem in the treatment of cancer and limits the
therapeutic use of this group of effective antineo-
plastic agents 1. To optimize ADR treatment in
patients and to prevent cardiac injury, the early
detection of cardiotoxicity is mandatory. Although
cardiotoxicity is frequently assessed by measuring
left ventricular ejection fraction (EF), EF is known
to be a rather insensitive measure of early cardiac
damage.1,2
Ultrasonic tissue characterization by integrated
backscatter offers a non-invasive means of deter-
mining the static and dynamic properties of the
myocardium. Normal myocardium shows car-
diac cycle dependent integrated backscatter var-
iations (CVIB). Moreover, CVIB reflects regional
and intramural contractile performance, and its
magnitude decreases in both ischemic3-8 and non-
ischemic9-13 myocardial diseases. We hypothe-
sized that CVIB might be decreased earlier than
EF in rats with ADR-induced cardiomyopathy.
Therefore, we investigated whether the serial as-
sessment of the acoustic properties of the myo-
cardium enables the earlier detection of myocar-
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dial damage after ADR chemotherapy.
MATERIALS AND METHODS
Experimental animals
ADR-cardiomyopathy was induced in 40 male
Wistar rats weighing 230 ± 25g by the weekly
administration of 2 mg/kg of ADR (supplied by
Kyowa Hakko Kogyo Co. Ltd.) via a tail vein for
8 weeks. The control group was comprised 20
Wistar rats, which were treated with the same
volume of normal saline. Batches of 3 rats were
euthanized 24 hours after starting ADR or saline
administration and also on the same day of weeks
2, 4, 6, and 8 (Week 0 was taken to be the time
of the first administration of ADR). Echocardio-
graphic examinations were performed after the
induction of anesthesia with an intraperitoneal
injection of ketamine (70 mg/kg). Left ventricular
(LV) performance was examined by echocardio-
graphy at baseline and weeks 2, 4, 6, and 8 after
the first injection of ADR or saline. LV dimensions
(end-diastolic and end-systolic diameter) were
measured by M-mode echocardiography at para-
sternal short axis image at the papillary muscle
level. The EF was calculated by M-mode echocar-
diography, using a modification of the method
described by Quinones et al.14
Integrated backscatter images
Integrated backscatter images were obtained
using a real time two dimensional ultrasonic back-
scatter imaging device (Sonos 2500, Philips,
Andover, Massachusetts) equipped with an acous-
tic densitometry measurement package for back-
scatter signal analysis. This system allows the
operator to acquire and store a sequence of con-
tinuous two dimensional integrated backscatter
images on an optical disk for subsequent analysis.
Off-line analysis of the backscatter images was
performed by retrieving a stored real time cine
loop data from the system's built-in optical disc
drive. Integrated backscatter was determined
using the cine loop of the LV parasternal short
axis view (Fig. 1). An elliptical region of interest
of 31 × 31 pixels was placed in the mid anterior
septum and at the posterior wall of the mid-LV.
The largest region of interest was chosen to cover
the myocardium whilst avoiding specular echoes
from the endocardium or epicardium. All controls
were held constant during the studies in each
subject. The magnitude of CVIB was defined as
the difference between minimum and maximum
values in a cardiac cycle averaged over at least
two consecutive beats. We used a specialized 5 -
12 MHz broadband transducer (S12 transducer,
Philips, Andover, Massachusetts), which allows
the high-resolution imaging of fine cardiac struc-
tures at shallow depths of 0 - 4 cm. Intraobserver
Fig. 1. Two-dimensional integrated back-
scatter image from parasternal short-axis
view at the papillary muscle level and
integrated backscatter measurements at the
interventricular septum and posterior wall.
An elliptical region of interest of 31 × 31
pixels was placed in the mid anterior sep-
tum (upper left) and the posterior wall (up-
per right) of the mid-LV. The largest region
of interest was chosen to cover the myo-
cardium whilst avoiding specular echoes
from the endocardium or epicardium.
Cyclic Variation of Integrated Backscatter in Adriamycin-Induced Cardiomyopathy 75
Yonsei Med J Vol. 46, No. 1, 2005
and interobserver variability of the magnitude of
CVIB were assessed by having the study observer
and two independent observers measure its mag-
nitude in 10 randomly selected subjects. The mean
absolute differences in the CVIB magnitudes were
0.3 ± 0.4 dB (intraobserver) and 0.4 ± 0.4 dB (inter-
observer).
Histological assessment of myocardial damage
After anesthesia with ether, chests were opened
and hearts immediately isolated. Blood in hearts
were removed and hearts weighed. Ventricles
were cut horizontally and separated into 3 slices.
Ventricle mid-slices were fixed in 4% paraformal-
dehyde at 4 for 8 hours, dehydrated in graded
alcohol series, and then embedded in paraffin.
The apical and basal portions of LVs were rapidly
frozen in liquid nitrogen and preserved at -80
until use. A portion of each LV was also em-
bedded in OCT compound and rapidly frozen.
Paraffin sections (3 m) were stained with hemaμ -
toxylin and eosin and with Masson's trichrome
stain.
Statistical analysis
Categorical data, expressed as percentages, were
compared using the Chi Square test. Continuous
variables, expressed as means ± SD, were com-
pared by the 2-sample Wilcoxon rank sum test.
RESULTS
No significant difference in EF measured at
baseline (80% vs 81%), 2 weeks (82% vs 81%), 4
weeks (80% vs 78%) or 6 weeks (82% vs 80%)
was observed between the ADR group and the
saline-treated controls. However, the LVEF of
the ADR group measured at 8 weeks (57%), was
significantly lower than that of the control group
(75%) (Fig. 2). Similarly, no significant differ-
ences were observed between the two groups
with respect to LV end-systole and diastolic
dimensions, or in the wall thicknesses of the
interventricular septum or posterior wall until 6
weeks after ADR. However, LV end-systolic and
diastolic dimensions were significantly greater in
the ADR group subjects at 8 weeks. H&E
staining revealed no significant abnormality in
control group or in the ADR group until 6
weeks. Prominent pathologic abnormalities, such
as focal fibrosis, were seen at 8 weeks only.
CVIB of the septum and posterior wall did not
change significantly with time (Fig. 3, 4) in
either group. No significant differences in the
CVIBs of septums or posterior wall were ob-
served between the 2 groups at baseline or from
2 to 8 weeks after ADR or saline treatment.
Fig. 3. Time-course of integrated backscatter cyclic
variations of the integrated backscatter of interventricular
septum in the adriamycin and the control groups.
Fig. 2. Time-course left ventricular ejection fraction
changes in the adriamycin and saline-treated control
groups.
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DISCUSSION
The principal finding of this study is that the
serial assessment of the acoustic properties of the
myocardium did not detect myocardial damage
earlier after doxorubicin chemotherapy in a rat
model. Thus, CVIB may not be an optimal or sen-
sitive tool for the early detection of myocardial
damage after doxorubicin chemotherapy. More
sensitive techniques are thus needed to detect
early ADR-induced myocardial damage.
The risk of inducing cardiac abnormalities in-
cluding the development of heart failure even
years after treatment as a result of doxorubicin
therapy has been recognized for a long time 1.
Suitable tests are needed to adapt chemotherapy
schedules and to monitor supportive cardiac
treatment. However, no highly sensitive screening
method capable of predicting cardiac dysfunction
exists. Currently, LVEF measured by radionuclide
ventriculography or echocardiography is used to
detect or exclude cardiac damage in cancer
patients treated with doxorubicin. However, LVEF
measurement is relatively insensitive for detecting
doxorubicin induced cardiotoxicity at an early
stage.1,2 This is largely because no considerable
change in systolic function occurs until a critical
amount of morphological damage has taken place.
Moreover, after this point deterioration proceeds
rapidly and prognosis is poor.
Collagen is a primary determinant of both the
scattering and the attenuation of myocardial tis-
sue. A linear relationship was found between inte-
grated backscatter and the hydroxyproline content
in autopsied human heart, where fibrotic changes
were associated with remote myocardial infarc-
tion. Echocardiographic tissue characterization
can identify changes in myocardial acoustic pro-
perties related to myocardial histologic changes.
CVIB is affected in ischemic heart disease,3,5,6
cardiomyopathies,9,10,15,16 cardiac allograft rejec-
tion,11,17 and in the diabetic heart.12,18 The relation-
ship between myocardial wall thickening and
CVIB magnitude is complex. CVIB magnitude is
not linearly related to myocardial systolic wall
thickening in dogs with coronary occlusion fol-
lowed by reperfusion, 19 or in human hypertro-
phied hearts.9 Thus, CVIB is dependent not only
on wall thickening, but also on intrinsic myo-
cardial properties, which cannot be visually as-
sessed by conventional echocardiography. Our
hypothesis was that histologic changes occur at
lower doses of doxorubicin, and that these
changes may alter myocardial acoustic properties
but not LV global function. If true, myocardial
tissue characterization would detect changes of
myocardial dysfunction at an earlier stage. How-
ever, in our study, subjects treated with moderate
doses of doxorubicin did not show a reduced CV-
IB despite a reduced systolic function. Recently, in
contrast to our results, Nagai et al.19 demonstrated,
in patients who were receiving anthracycline for
non-Hodgkin's lymphoma, that CV-IB was re-
duced in some patients treated with a moderate
dose of doxorubicin, and thus they suggested that
CV-IB analysis might be helpful for detecting
early anthracycline cardiotoxicity. Further study is
needed to confirm these findings.
In conclusion, the serial assessment of the
acoustic properties of the myocardium failed to
detect early myocardial damage after doxorubicin
chemotherapy in a rat model. We believe that
more sensitive techniques are needed for the early
detection of ADR-induced myocardial damage.
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